First Header Logo Second Header Logo

Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.

Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2017 12 01; 16(12):1246-1252.

View in: PubMed